The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Open accessAbstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2009, Pasi et al. identified a series of covalent pyrimidine EGFR inhibitors, including WZ 3146, WZ 4002, and WZ 8040, through screening a library of irreversible kinase inhibitors specific to EGFRT790M.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [203]
In the citing paper
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [34]
In the citing paper
“C797 is located opposite T790 in the ATP binding pocket and forms a covalent bond with all third-generation TKIs and is necessary for the inhibitor to suppress EGFR (21).”
In the citing paper
“This approach has previously led to identification of clinically relevant drug resistance mutations to EGFR TKIs (30, 31).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [30]
In the citing paper
“Thus, the T790M structural alteration in essence “enabled” discovery of inhibitors that selectively inhibit T790M–bearing mutants, when in association with L858R or exon 19 deletions, relative to WT EGFR 58,59.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [58]
In the citing paper
“Examination of the crystal structure of WZ4002 in complex with EGFR T790M (14) reveals that both L718 and L844 are in direct contact with the inhibitor; L718 primarily with the aniline ring and L844 with the pyrimidine ring (Figure 2A).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“C797 is the site of covalent binding of WZ4002 and previously demonstrated to lead to drug resistance if mutated to serine (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“However, ENU mutagenesis studies have been predictive of clinical drug resistance mutations in several prior studies (14, 24).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“In prior studies, introduction of C797S into the background of EGFR L858R/T790M or EGFR Del 19/T790M resulted in significant loss of cellular potency for WZ4002 (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Analogously, a non-covalent analogue of WZ4002, WZ4003, was ineffective in in vitro models of EGFR T790M (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“WZ4002 is a covalent pyrimidine EGFR inhibitor specifically designed against EGFR T790M that is 30–100 fold more potent against EGFR T790M, and up to 100 fold less potent against wild type EGFR than quinazoline based EGFR inhibitors in vitro and is effective in murine models of lung cancer driven by EGFR T790M [84].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [84]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [43]
In the citing paper
“Standard of care is rapidly changing with the development of third-generation, mutant-selective EGFR-TKIs that have activity against cells that harbor TKI-sensitive EGFR mutations. Unlike conventional EGFR-TKIs, this activity is maintained in the presence of T790M resistance mutation.8,9”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [9]
In the citing paper
“Next-generation EGFR TKIs have since been developed specifically to target the T790M mutation, 17,18 and they have demonstrated high and durable responses in patients with advanced EGFRmutant NSCLC who have been previously treated and in whom firstor second-generation EGFR TKIs have failed.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Self-citationBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Self-citationEngelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Gonçalves, C. D. N., da Rocha, M. N., & Marinho, E. S. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100164 · Cited by 10
From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer
Formisano, L., Jansen, V. M., Marciano, R., & Bianco, R. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520617666170912123416 · Cited by 10
Ye, X., Tang, G., & Song, G. (2014) · Surface and Coatings Technology · doi:10.1016/j.surfcoat.2014.11.028 · Cited by 10
RetractedKrawczyk, P. A., Mlak, R., Powrózek, T., Nicoś, M., Kowalski, D. M., Wojas‐Krawczyk, K., & Milanowski, J. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.31768 · Cited by 10
Maximizing the Benefits of Off-Target Kinase Inhibitor Activity
Brewer, M. R., & Pao, W. J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0581 · Cited by 10
QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
Fatima, S., Pal, D., & Agarwal, S. M. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13505 · Cited by 10
Protein Allostery in Rational Drug Design
Kinoshita, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_3 · Cited by 10
Sun, B., Liu, X., Zheng, X., Wang, C., Meng, Q., Sun, H., Shu, X. H., Liu, K., Sun, X., Li, Y., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900606 · Cited by 10
Ibrahim, M. T., Uzairu, A., Shallangwa, G. A., & Uba, S. (2021) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2021.1946650 · Cited by 10
Mao, Y.-Z., Xi, X.-X., Zhao, H., Zhang, Y., & Zhang, S. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129381 · Cited by 10
Peng, M., Weng, Y. M., Liu, H. L., Yang, G. F., Yao, Y., Han, G., & Song, Q. B. (2018) · BioMed Research International · doi:10.1155/2018/7181368 · Cited by 10
Yu, H., Liu, M., Qiu, H., & Yang, K. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.10.006 · Cited by 10
Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10
Thiazolidinedione derivatives: emerging role in cancer therapy
Latambale, G., & Juvale, K. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11093-3 · Cited by 9
Noda, S., & Kanda, S. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1164603 · Cited by 10
Park, H., Jung, H., Mah, S., & Hong, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201703389 · Cited by 9
Wu, S., Gow, C., Chen, Y., Liu, Y., Tsai, M., & Shih, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34507 · Cited by 9
Damghani, T., Wittlinger, F., Beyett, T. S., Eck, M. J., Laufer, S., & Heppner, D. E. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.03.013 · Cited by 9
Self-citationWang, L., An, Y., Wei, X., Huang, X., Tu, Y., Qiao, L., & Zhu, W. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2255654 · Cited by 9
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 10
Taus, Á., Vollmer, I., & Arriola, E. (2010) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2010.06.013 · Cited by 9
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents
Bao, R., & Chan (2011) · Journal of Experimental Pharmacology · doi:10.2147/jep.s7804 · Cited by 9
Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes
Shindoh, N., Yoda, A., Yoda, Y., Sullivan, T. J., Weigert, O., Lane, A. A., Kopp, N., Bird, L., Rodig, S. J., Fox, E. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049201 · Cited by 9
Genova, C., Rijavec, E., Biello, F., Rossi, G., Barletta, G., Bello, M. G. D., Vanni, I., Coco, S., Alama, A., & Grossi, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1261109 · Cited by 9
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707875 · Cited by 9
Mulshine, J. L., Ujházy, P., Antman, M., Burgess, C. M., Kuzmin, I., Bunn, P. A., Johnson, B. E., Roth, J. A., Pass, H. I., Ross, S. M., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29564 · Cited by 9
Saini, R. P., Fatima, S., & Agarwal, S. M. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13697 · Cited by 9
Chemical proteomic identification of functional cysteines with atypical electrophile reactivities
Litwin, K. M., Crowley, V. M., Suciu, R. M., Boger, D. L., & Cravatt, B. F. (2021) · Tetrahedron Letters · doi:10.1016/j.tetlet.2021.152861 · Cited by 9
AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Stinchcombe, T. E. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.07.19 · Cited by 9
Rosa, V. D., Iommelli, F., Monti, M., Mainolfi, C. G., Fonti, R., & Vecchio, S. D. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0229-0 · Cited by 9
Zhou, F., Zhang, L., Jin, Y.-Z., Liu, W., Cheng, P., He, X., Xie, J., Shen, S., Jing, L., Ji, H., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.009 · Cited by 9
SP3‐FAIMS‐Enabled High‐Throughput Quantitative Profiling of the Cysteinome
Desai, H. S., Yan, T., & Backus, K. M. (2022) · Current Protocols · doi:10.1002/cpz1.492 · Cited by 9
Ding, K., Li, Y., Zhou, Y., & Huang, W. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00496 · Cited by 8
Structure-informed machine learning for drug discovery: a task-centric perspective
Li, Y., Zhan, R.-H., Rao, J., Liu, M., Sang, P., Zeng, X., Zheng, M., Li, X., & Yang, L. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag081 · Cited by 8
In vivo PET Imaging of EGFR Expression: An Overview of Radiolabeled EGFR TKIs
Zhu, J., Li, Y., Wu, X., Li, Y., Wang, L., & Fan, H. X. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220903142416 · Cited by 8
Zhao, H., Beyett, T. S., Jiang, J., Rana, J. K., Schaeffner, I. K., Santana, J., Janne, P. A., & Eck, M. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417144121 · Cited by 8
Self-citationEpidermal growth factor receptor mutation‐guided treatment for lung cancers: Where are we now?
Su, Z. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00035.x · Cited by 8
Taus, Á., Vollmer, I., & Arriola, E. (2011) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(11)70021-0 · Cited by 8
Du, Z., Sun, J., Zhang, Y., Hesilaiti, N., Xia, Q., Cui, H., Fan, N., & Xu, X. (2023) · Biomolecules · doi:10.3390/biom13020210 · Cited by 9
Fukuda, H., Zou, T., Fujii, S., Sato, S., Wakahara, D., Higashi, S., Tseng, T., Chang, T., Yada, N., Matsuo, K., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad211 · Cited by 8
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Sakanyan, V. A., Iradyan, N., & de Sousa, R. A. (2023) · BioTech · doi:10.3390/biotech12030057 · Cited by 8
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
Rosell, R., Morán, T., Viteri, S., Carcereny, E., Gascó, A., Quiroga, V., Wei, J., Camps, C., & Massutí, B. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.482101 · Cited by 9
Wang, C., Xu, S., Liang, P., Zhang, B., Zhang, H., Hu, Y., Zheng, P., & Zhu, W. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1518957 · Cited by 8
Maneiro, M., Lence, E., Sanz‐Gaitero, M., Otero, J. M., van Raaij, M. J., Thompson, P., Hawkins, A. R., & González‐Bello, C. (2019) · Organic Chemistry Frontiers · doi:10.1039/c9qo00453j · Cited by 8
Lu, X. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00012-7 · Cited by 7
Bioluminescence-based assays for quantifying endogenous protein interactions in live cells
Niles, A. L., Dibble, M., Machleidt, T., Martino, K., Swiatnicki, M., Vu, E. H., & Schwinn, M. K. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110454 · Cited by 7
Shevate, K. S., Rajagopal, K., Byran, G., Mandala, S., Antony, J., & Gurunathan, M. (2025) · Peptide Science · doi:10.1002/pep2.70012 · Cited by 7
Zhang, R., Chen, S., Zhang, X., Yu, R., Wan, S., Geng, M., & Jiang, T. (2016) · RSC Advances · doi:10.1039/c6ra06818a · Cited by 7
Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR
Kuang, Y., O’Connell, A., Sacher, A. G., Feeney, N. B., Alden, R. S., Oxnard, G. R., & Paweletz, C. P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7778-9_12 · Cited by 7
Steering Target Selectivity and Potency by Fragment‐Based De Novo Drug Design
Rodrigues, T., Kudoh, T., Roudnicky, F., Lim, Y. F., Lin, Y., Koch, C. P., Seno, M., Detmar, M. J., & Schneider, G. (2013) · Angewandte Chemie · doi:10.1002/ange.201304847 · Cited by 7
Selective Kinase Inhibitors in Cancer
Mortlock, A. A., Wilson, D. M., Kettle, J. G., Goldberg, F. W., & Foote, K. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12391-1 · Cited by 7
Mi, J., Huang, Z. D., Zhang, R., Zeng, L., Xu, Q., Yang, H., Lizaso, A., Tong, F., Dong, X., Yang, N., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100347 · Cited by 7
Wang, L., Ding, X., Wang, K., Sun, R., Li, M., Wang, F., & Xu, Y. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134499 · Cited by 7
Aljohani, A. K. B., El‐Adl, K., Almohaywi, B., Alatawi, O. M., Alsulaimany, M., El-morsy, A., Almadani, S. A., Alharbi, H. Y., Aljohani, M. S., Felemban Athary Abdulhaleem, M., et al. (2024) · RSC Advances · doi:10.1039/d4ra00502c · Cited by 7
Activating Mutations and Targeted Therapy in Cancer
Tuna, M., & Christopher, I. L. (2012) · InTech eBooks · doi:10.5772/48701 · Cited by 8
Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Dagogo‐Jack, I., Engelman, J. A., & Shaw, A. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122044 · Cited by 7
Small Molecule Inhibitors of the Epidermal Growth Factor Receptor
Finlay, M. R. V., & Ward, R. A. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_26 · Cited by 7
Akher, F. B., Farrokhzadeh, A., & Soliman, M. E. S. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13467 · Cited by 7
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Ma, X., Wu, S., Li, B., Zhang, Q., Zhang, J., Liu, W., Yan, H., Bernards, R., Qin, W., & Wang, C. (2022) · Cell Discovery · doi:10.1038/s41421-022-00425-y · Cited by 7
Visual DNA microarray for detection of epidermal growth factor receptor (EGFR) gene mutations
Li, X., Fei, J.-J., Song, Y., Xu, R., & Bai, Y. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.951680 · Cited by 7
Yi, Y., Wang, L., Zhao, D. Y., Huang, S., Wang, C., Liu, Z., Sun, H., Liu, K., Ma, X., & Li, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13370 · Cited by 7
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 8
A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinasePreprint
Giglio, R. M., Hou, N. Y., Shi, L., Wyatt, A., Hong, J., Vaikunthan, M., Bellamy, C., Fuchs, H., Lu, V., Obasi, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.08.587960 · Cited by 7
Günther, M., Juchum, M., Kelter, G., Fiebig, H. H., & Laufer, S. (2016) · Angewandte Chemie · doi:10.1002/ange.201603736 · Cited by 6
Ahmad, I., & Patel, H. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70077 · Cited by 6
Samanta, A., Maji, A., Paul, A., Mishra, S. S., Nahar, S., & Maity, T. K. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100265 · Cited by 6
Kumar, V., Chauhan, L., Singh, D., Kumar, A., Kulandaisamy, R., Kushwaha, T., Baswal, K., Singh, R., Kumar, S., Gholap, S. L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570108 · Cited by 6
Goggi, J., Haslop, A., Ramasamy, B., Cheng, P. K. C., Jiang, L., Soh, V., & Robins, E. G. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3771 · Cited by 6
Bahi, S. E., Boutalaka, M., Alaqarbeh, M., Alaouy, M. A. E., Koubi, Y., Khatabi, K. E., Choukrad, M., Sbai, A., Bouachrıne, M., & Lakhlifi, T. (2023) · Chemistry Africa · doi:10.1007/s42250-023-00744-x · Cited by 7
Kale, A. D., Pawara, R. H., Patel, H., & Dalal, D. S. (2023) · Research on Chemical Intermediates · doi:10.1007/s11164-023-05188-z · Cited by 6
Wong, C. F. (2015) · Protein Science · doi:10.1002/pro.2716 · Cited by 6
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
Hu, Z., Hu, Y., Liu, X., Xi, R., Zhang, A., Liu, D., Xie, Q., & Chen, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5221 · Cited by 6
Self-citationNarayanan, D., Gani, O. A. B. S. M., Gruber, F., & Engh, R. A. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0229-8 · Cited by 6
Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines
Wang, C., Liu, X.-W., Xiao, T., Xu, Z., Cao, S., Wang, H., Yan, Q., Gu, S., & Zhu, Y. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02531-6 · Cited by 6
Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain
Mozumdar, D., Doerner, A. E., Zhang, J. Y., Rafizadeh, D. N., & Schepartz, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00641 · Cited by 6
Liu, B., Qin, J., Yin, Y., Zhai, L., Liu, G., Lizaso, A., & Shi, D. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7626 · Cited by 6
Contextualizing Genes by Using Text-Mined Co-Occurrence Features for Cancer Gene Panel Discovery
Chen, H.-O., Lin, P., Liu, C.-R., Wang, C.-S., & Chiang, J.-H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.771435 · Cited by 6
Barker, A. J., & Andrews, D. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397176-0.00008-x · Cited by 6
Frett, B., Carlomagno, F., Moccia, M. L., Brescia, A., Federico, G., Falco, V. D., Admire, B., Chen, Z., Qi, W., Santoro, M. M., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501104 · Cited by 6
Synthesis of p‐O‐Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors
Zhang, L., Hou, L., Sun, W., Yu, Z., Wang, J., Gao, H., & Yang, G. (2016) · Drug Development Research · doi:10.1002/ddr.21290 · Cited by 6
Han, C., Ren, J., Su, F., Hu, X., Li, M., Wang, Z., & Wu, L. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200302113206 · Cited by 6
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Mitsudomi, T., & Suda, K. (2013) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s49603 · Cited by 6
Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Huang, S., Rodemann, H. P., & Harari, P. M. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-662-49651-0_3 · Cited by 6
El-Hema, H. S., Fekey, H. M. E., Hawata, M. A., Hussein, M. F., Elhendawy, A. T., & Abdel‐Rahman, A. A. ‐. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145461 · Cited by 5
Wang, Y., Nan, X., Duan, Y., Wang, Q., Liang, Z., & Yin, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117870 · Cited by 5
Konsue, A., Lamtha, T., Gleeson, D., Jones, D. J. L., Britton, R. G., Pickering, J., Choowongkomon, K., & Gleeson, M. P. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117906 · Cited by 5
Kinase-Targeted Therapies for Glioblastoma
Salbini, M., Formato, A., Mongiardi, M. P., Levi, A., & Falchetti, M. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083737 · Cited by 5
Brace, G. N., Tillack, K., Johnson, P. D., Ritzefeld, M., Schaertl, S., Frush, E. H., Warfield, B. M., Ballantyne, G., Lee, J., Thieulin‐Pardo, G., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130326 · Cited by 5
Poullennec, K. G., Jnoff, E., Abendroth, J. A., Bhuma, N., Calmiano, M., Calmus, L., Cardenas, A., Courade, J., Delatour, C., Hall, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01237 · Cited by 5
An overview of phenylsulfonylfuroxan-based nitric oxide donors for cancer treatment
Gao, C., Li, X., Liu, T., Wang, W., & Wu, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108020 · Cited by 5
Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Reid, T.-E. R., Fortunak, J., Wutoh, A., & Wang, X. S. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150915120814 · Cited by 5
Guillaume, J., Benjamin, F., Jean-Gilles, M., Ajah, M., Tabassi, G., & Kenel-Pierre, C. S. (2000) · PubMed · Cited by 5
Chen, H., Song, P., Diao, Y., Hao, Y., Dou, D., Wang, W., Fang, X., Wang, Y., Zhao, Z., Ding, J., et al. (2018) · MedChemComm · doi:10.1039/c8md00019k · Cited by 5
Implications of the HDAC6-ERK1 feed forward loop in immunotherapy
Zhang, X. M. (2018) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2018/3.1143 · Cited by 5
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00710 · Cited by 5
Khattri, R. B., Morris, D. L., Bilinovich, S. M., Manandhar, E., Napper, K. R., Sweet, J. W., Modarelli, D. A., & Leeper, T. C. (2019) · Molecules · doi:10.3390/molecules25010147 · Cited by 5
Wang, J., Huang, L., Chen, X., Yuan, Y., Sun, J., & Yang, M. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00303 · Cited by 5
Cao, Y., Lu, X., Fu, L., Shi, T., Zhang, C., Zeng, L., Zhang, J., Shao, J., Xi, J., Pan, Z., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106494 · Cited by 5
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
Self-citation
Metadata
- Authors
- Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K.-K., Eck, M. J., Gray, N. S., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Northeastern University (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Nature
- Published
- 2009-12
- Volume
- 462
- Issue
- 7276
- Pages
- 1070-1074
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2879581
- OpenAlex
- W2133963438
- Cited by
- 1,013
- References
- 30
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 46 · 2021: 55 · 2020: 62 · 2019: 55 · 2018: 66 · 2017: 84 · 2016: 82 · 2015: 75 · 2014: 71 · 2013: 82 · 2012: 54
- FWCI
- 45.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (R01AG2400401)
- National Cancer Institute (R01CA116020, R01CA122794, R01CA130876, R01CA11446, P50CA090578, R01CA135257, R01CA080942)
- National Institute of General Medical Sciences (R01GM070590)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- EGFR kinase inhibitors, mutant-selective inhibitors, irreversible kinase inhibitors, non-small cell lung cancer, drug resistance, co-crystallization, gatekeeper mutation
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Lung, Models, Chemical, Models, Molecular, Mutation, Phosphorylation, Drug Resistance, Neoplasm, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
